The Official Newsletter ofCentinel Spine®

Centinel Spine® Announces Record Revenue in Second Quarter 2024 as prodisc® Total Disc Replacement Momentum Continues

Steve Sanderson

Record worldwide prodisc Total Disc Replacement (TDR) revenue exceeding $22 million in Q2 2024, growing almost 30% over prior year.

Centinel Spine recently announced achievement of record revenue in the second quarter of 2024—outperforming Q1 2024, its previous record quarter.

Centinel Spine remains the fastest growing company in the spine industry* and is dedicated exclusively to total disc replacement (TDR), one of the fastest growing segments in orthopedic implants.

Second Quarter 2024 Highlights

  • Record worldwide prodisc TDR revenue of $22.1 million, representing 26% year-over-year (YOY) growth.
  • Record worldwide prodisc Cervical revenue of $14.6 million, with 32% YOY growth.
  • Record U.S. prodisc Cervical revenue, with 42% YOY growth.
  • Record U.S. prodisc total surgeon user-base of nearly 600 surgeons, representing almost 40% YOY growth and sequential quarterly user growth of 10%. Q2 2024 was the 8th consecutive quarter of surgeon user growth.

Highlights on the New Match-the-Disc™ prodisc C Vivo & prodisc C SK Cervical System

  • Nearly 7,000 procedures have been completed with the new system since limited US release in Q3 2022.
  • Record prodisc C Vivo and prodisc C SK revenue in Q2 2024, representing nearly 67% and 100% YOY growth, respectively.
  • Added record number of new surgeons using the Match-the-Disc prodisc C Vivo and prodisc C SK cervical system in Q2 2024, increasing the total number of surgeons that have utilized the new system by nearly 140% YOY and almost 20% in sequential quarterly growth.
  • Over 75% of the nearly 700 surgeons that have utilized the new system to date are repeat users and a strong majority of surgeon users come from competitive conversions.

 

* Based on publicly available information.

M
M

If you have further questions, contact:

More From Centinel Spine:
The Big Story
Centinel Spine Receives 2-Level FDA Approval for prodisc® C Vivo & prodisc® C SK Match-the-Disc™ Cervical Total Disc Replacement Devices
Read On
The Big Story
Centinel Spine® Grows prodisc® Total Disc Replacement 42% Worldwide in Third Quarter 2025 with Record EBITDA Results
Read On
Centinel Spine® Receives MDR Certification for prodisc® C Vivo & prodisc® C Nova Cervical Total Disc Replacement Systems
Read On
Centinel Spine in the News: Centinel Spine's prodisc® Revolution—Redefining Motion Preservation in 2025
Read On
Q3 2025 Medical Education Event Recap
Read On
WATCH:
Centinel Spine - CSRS Cadaveric Surgical Technique Video Featuring prodisc® C Vivo
Read On
New Surgeon Blog Post Educates on Non-Surgical Ways to Relieve Neck Pain
Read On